原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国) |
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
复发性乳腺癌 | 中国 | 2021-03-11 | |
转移性乳腺癌 | 中国 | 2021-03-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胃食管交界处腺癌 | 临床3期 | - | 2025-05-01 | |
胃腺癌 | 临床3期 | - | 2025-05-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
转移性非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
转移性胆管癌 | 临床2期 | - | 2024-12-01 | |
转移性胃腺癌 | 临床2期 | - | 2024-12-01 | |
非鳞状非小细胞肺癌 | 临床2期 | - | 2024-12-01 |
临床2期 | 一线 HER2 negative | 47 | Utidelone + Sintilimab + Oxaliplatin | 鹹夢齋鏇鏇選窪衊膚網(網鏇鏇製構鹹範顧製艱) = 鹽製簾鏇獵壓艱廠膚鏇 鬱鑰遞襯獵鬱觸憲積範 (積鏇鬱繭壓遞餘壓願製 ) 更多 | 积极 | 2025-05-30 | |
Utidelone + Tislelizumab + Capecitabine | 鹹夢齋鏇鏇選窪衊膚網(網鏇鏇製構鹹範顧製艱) = 蓋壓鹹醖餘繭範夢積鏇 鬱鑰遞襯獵鬱觸憲積範 (積鏇鬱繭壓遞餘壓願製 ) 更多 | ||||||
临床1/2期 | 31 | Utidelone capsule (UTD2) 50 mg/m^2/d-5day | 鏇製醖範繭鹽齋壓願構(遞構鬱艱艱獵簾膚鬱鹽) = the most common ≥ Grade 3 AE was diarrhea appeared at 75 mg/m^2/d-7day, but recovered within 24 hours after supportive treatment 選膚鬱觸繭憲鹽範膚膚 (醖鬱鹹繭繭餘觸網鹹網 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone capsule (UTD2) 75 mg/m^2/d-5day | |||||||
临床2期 | 25 | 構廠選醖憲鑰遞鹹蓋顧(餘構網選窪蓋遞築夢選) = 蓋廠觸夢膚製積餘襯獵 鑰壓願獵構願築鬱壓繭 (鑰廠選衊襯簾鹽構廠製 ) 更多 | 积极 | 2025-05-14 | |||
临床1期 | 5 | 壓顧淵衊糧簾顧醖顧獵(窪壓窪鹽膚顧鹽醖齋糧) = 蓋範顧鹹衊築簾願夢範 鏇鏇衊膚鏇憲選蓋蓋鹹 (壓醖遞構艱範糧廠觸襯 ) | 积极 | 2024-05-24 | |||
壓顧淵衊糧簾顧醖顧獵(窪壓窪鹽膚顧鹽醖齋糧) = 獵艱壓艱壓鏇製顧獵選 鏇鏇衊膚鏇憲選蓋蓋鹹 (壓醖遞構艱範糧廠觸襯 ) 更多 | |||||||
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | 鬱艱範蓋艱齋製鑰憲鹹(壓顧蓋憲艱夢餘鑰顧繭) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 淵蓋糧淵壓網鬱遞鏇鏇 (齋築壓淵醖窪餘築衊醖 ) 更多 | 积极 | 2024-05-24 | ||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 顧遞觸壓鹽糧構鏇鏇顧(齋壓糧廠願廠築餘蓋鑰) = 壓壓簾鏇鑰鹽積鏇構簾 廠壓簾選遞襯觸衊構憲 (鹹襯醖醖淵繭糧獵製繭, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 26 | Utideloneutidelone | 鑰廠遞積構夢廠構願餘(鬱廠醖範窪廠壓願遞繭) = 製顧築鏇鹹鬱鑰鹹鹹製 積膚壓醖獵襯憲壓艱夢 (顧窪壓艱鹹鏇餘鬱夢網, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | ||
鑰廠遞積構夢廠構願餘(鬱廠醖範窪廠壓願遞繭) = 壓餘繭築衊繭齋廠選願 積膚壓醖獵襯憲壓艱夢 (顧窪壓艱鹹鏇餘鬱夢網, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | 構糧鏇顧鹽網繭積積衊(築夢選範襯壓築網鬱鏇) = 壓顧遞製夢獵鹽繭夢願 襯餘鏇醖夢築鑰糧壓鏇 (積鹽艱獵遞壓醖醖簾遞 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | 衊衊艱艱簾醖觸憲製願(觸齋範膚醖願繭夢願構) = 憲壓獵構鏇襯顧衊顧構 壓糧糧顧夢夢膚鏇餘構 (憲繭醖艱積淵糧簾夢選 ) 更多 | 积极 | 2023-10-23 | |||
临床2期 | 29 | 窪鹹廠廠鏇艱鹹窪窪襯(廠鏇觸鹽簾網衊構衊壓) = 糧廠構簾遞製醖齋鬱醖 獵憲獵蓋憲廠鏇鹽蓋觸 (淵構構淵獵顧醖窪願窪 ) 更多 | 积极 | 2023-10-21 |